Atıf İçin Kopyala
ÇELİK B., Yalcin A. D., Bisgin A., Dimitrakopoulou-Strauss A., Kargi A., Strauss L. G.
MEDICAL SCIENCE MONITOR, cilt.19, ss.875-882, 2013 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
19
-
Basım Tarihi:
2013
-
Dergi Adı:
MEDICAL SCIENCE MONITOR
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.875-882
-
Anahtar Kelimeler:
metastatic colorectal cancer (MCRC), CXCL8 (IL8), soluble TRAIL (sTRAIL), anti VEGF antibody (Bevacizumab), F-18-Deoxyglucose positron emission tomography (FDG-PET/CT), proteomics study, (SUVmax: standardized uptake maximum values), COLORECTAL-CANCER, IN-VITRO, GENE-EXPRESSION, BEVACIZUMAB, TRAIL, INTERLEUKIN-8, ANGIOGENESIS, IMPACT, TUMORS, VIVO
-
Akdeniz Üniversitesi Adresli:
Evet
Özet
Background: The changes and correlations of TRAIL (TNF-related apoptosis-inducing-ligand) and CXCL8 (IL8) prior to treatment and three months following therapy as well as the corresponding Positron emission tomography (PET/CT) (SUVmax: standardized uptake maximum values) results were evaluated.